Effect of Probiotic Bacteria on Oral Candida in Frail Elderly
Effect of Probiotic Bacteria (L. Reuteri) on Oral Candida Counts in Frail Elderly
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- non-smoking
- ability to cooperate with a dental examination and saliva sampling
Exclusion Criteria:
- severe chronic disease, malignancies or ongoing medication with immunosuppressive drugs
- severe dementia or cognitive impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: L. reuteri DSM 17938/ATCC PTA
L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
|
Ingestion of active lozenge twice daily for 12 weeks
|
|
Placebo Comparator: Placebo
Placebo lozenges twice daily for 12 weeks
|
Ingestion of placebo lozenge twice daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of oral Candida growth assessed from chair-side tests.
Time Frame: Baseline and 12 weeks.
|
Saliva and plaque samples will be analyzed and data presented when all 215 participants have completed the intervention period.
|
Baseline and 12 weeks.
|
|
Amount of oral Candida growth assessed from chair-side tests.
Time Frame: Baseline and 12 weeks.
|
Saliva and plaque samples will be analyzed and data presented when all 215 participants have completed the intervention period.
|
Baseline and 12 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in levels of dental plaque
Time Frame: Baseline and 12 weeks.
|
Secondary Outcome Measures will be measured before and after the intervention period.
|
Baseline and 12 weeks.
|
|
Changes in levels of gingival bleeding.
Time Frame: Baseline and 12 weeks.
|
Secondary Outcome Measures will be measured before and after the intervention period.
|
Baseline and 12 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Svante Twetman, Professor, University of Copenhagen
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2010/618
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.